Roche Holding Ltd ADR (RHHBY)

42.99
-0.23(-0.54%)
After Hours
43.12
+0.13(+0.30%)
- Delayed Data
  • Volume:
    2,119,154
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    42.96 - 43.46

RHHBY Overview

Prev. Close
43.22
Day's Range
42.96-43.46
Revenue
68.86B
Open
43.36
52 wk Range
39.33-53.86
EPS
2.1
Volume
2,119,154
Market Cap
280.54B
Dividend (Yield)
0.7765
(1.80%)
Average Vol. (3m)
2,392,852
P/E Ratio
19.97
Beta
0.51
1-Year Change
0.16%
Shares Outstanding
800,403,291
Next Earnings Date
Jul 21, 2022
What is your sentiment on Roche Holding ADR?
or
Market is currently closed. Voting is open during market hours.

Roche Holding Ltd ADR News

Roche Holding Ltd ADR Analysis

Roche Holding Ltd ADR Company Profile

Roche Holding Ltd ADR Company Profile

Employees
100920

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women’s health. In addition, the company supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. It has collaboration with Gilead Sciences, Inc. for COVID-19; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company also has a collaboration with Bristol Myers Squibb to advance personalized healthcare through digital pathology solutions. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellNeutralSellNeutral
Technical IndicatorsStrong SellStrong SellBuyStrong BuySell
SummaryStrong SellStrong SellNeutralNeutralNeutral
  • it will go up: the chart formed an "bulllish doji star"
    0
    • This Is one and only real competitor in covid test from POLAND http://scopefluidics.com/scope-fluidics-is-developing-an-ultra-fast-covid-19-panel-for-its-pcrone-rapid-molecular-diagnostic-system/
      0
      • Roche just announced as the test pushed through for Covid 19 Tessting. Up Up Up!
        1
        • Jan 26, 2020 Sun $41.20 its GENE is dazzling as always focusing on breakthrough sciences
          0